You are here

psoriasis

Will Ilumya Kill Valeant's Psoriasis Dreams?

Will Ilumya Kill Valeant's Psoriasis Dreams?

Seeking Alpha

Valeant Pharmaceuticals

Flag link:

Sun Pharma Receives Approval for New Plaque Psoriasis Drug

Sun Pharma Receives Approval for New Plaque Psoriasis Drug

CP Wire

Flag link:

An immunotherapy pill for psoriasis? Escalier gets $19M Series B to tackle R&D

An immunotherapy pill for psoriasis? Escalier gets $19M Series B to tackle R&D

Endpoints

Flag link:

Novartis beefs up its data bank on Cosentyx’s durable effect on quality of life as well as scalp psoriasis

Novartis beefs up its data bank on Cosentyx’s durable effect on quality of life as well as scalp psoriasis

Endpoints

Flag link:

Novartis goes 2-0 against J&J in psoriasis

Novartis goes 2-0 against J&J in psoriasis

Biopharma Dive

Flag link:

Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar

Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar

Yahoo/Zacks.com

ankylosing spondylitis

Flag link:

In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst

In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst

Fierce Pharma

Flag link:

AbbVie's stock climbs after positive late-stage trial results of psoriasis treatment

AbbVie's stock climbs after positive late-stage trial results of psoriasis treatment

Marketwatch

clinical trials

Flag link:

A Me-Too Push By Biopharma Is Crowding the Psoriasis Market

A Me-Too Push By Biopharma Is Crowding the Psoriasis Market

Motley Fool

Flag link:

AbbVie boasts a PhIII sweep for top psoriasis contender risankizumab, but it has lots of competition

AbbVie boasts a PhIII sweep for top psoriasis contender risankizumab, but it has lots of competition

Endpoints

clinical trials

Flag link:

J&J psoriasis drug gets expanded U.S. approval for teens

J&J psoriasis drug gets expanded U.S. approval for teens

Yahoo/Reuters

Flag link:

Thync’s bioelectronics wearable shows promise in psoriasis pilot

Thync’s bioelectronics wearable shows promise in psoriasis pilot

Fierce Biotech

Flag link:

Novartis touts 5-year Cosentyx data as it works to hold top spot in psoriasis

Novartis touts 5-year Cosentyx data as it works to hold top spot in psoriasis

Fierce Pharma

Flag link:

Dr. Reddy's sells off psoriasis candidate in out-licensing deal

Dr. Reddy's sells off psoriasis candidate in out-licensing deal

BioPharma Dive

Encore Dermatology

Flag link:

J&J's Tremfya approved, further crowding IL-inhibitor market

J&J's Tremfya approved, further crowding IL-inhibitor market

BioPharma Dive

Interleukin-inhibitors

Flag link:

FDA clears Philips' light therapy wearable for mild psoriasis

FDA clears Philips' light therapy wearable for mild psoriasis

Fierce Biotech

Flag link:

J&J gets a quick FDA OK for its blockbuster psoriasis contender guselkumab

J&J gets a quick FDA OK for its blockbuster psoriasis contender guselkumab

Endpoints

Flag link:

Will Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around?

Will Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around?

Motley Fool

Valeant Pharmaceuticals

Flag link:

Black box warning? No worries, Valeant bills Siliq as the ‘low-cost’ psoriasis alternative to rivals from Novartis, Eli Lilly

Black box warning? No worries, Valeant bills Siliq as the ‘low-cost’ psoriasis alternative to rivals from Novartis, Eli Lilly

Endpoints

Valeant Pharmaceuticals

Flag link:

How a $37,000-a-year medicine sets a good model for drug pricing

How a $37,000-a-year medicine sets a good model for drug pricing

Stat

Flag link:

Pages